AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy

 AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy

AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy

Shots:

  • AbbVie and Idera collaborated to conduct clinical study evaluating the combination of ABBV-368 + tilsotolimod + CT or ABBV-181. AbbVie will be responsible for conducting the trial while Idera to provide clinical trial supply of tilsotolimod
  • The P-Ib study will evaluate the safety, tolerability, PK and preliminary efficacy of ABBV-368 plus tilsotolimod in three different arms in patients with recurrent or metastatic head and neck squamous cell carcinoma
  • Abbvie’s ABBV-368 is anti-OX40 mab, being evaluated in P-I study for solid tumors. ABBV-181 is an anti-PD1 mAb, being developed in combinations with other AbbVie’s molecules for solid tumors and hematologic malignancies while tilsotolimod is a TLR-9 agonist developed by Idera for multiple cancer indications

Click here to­ read full press release/ article | Ref: Idera | Image: Chicago Tribune

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post